dihydropyridines and Flushing

dihydropyridines has been researched along with Flushing* in 2 studies

Trials

1 trial(s) available for dihydropyridines and Flushing

Article	Year
Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial. Blood pressure. Supplement, 2003, Volume: 1 The objective of this 8-week open-label study was to compare the tolerability of lercanidipine, a dihydropyridine calcium-channel antagonist (CA), with that of other CAs in the treatment of hypertension. Subjects already taking amlodipine, felodipine, nifedipine gastrointestinal therapeutic system (GITS), or nitrendipine and experiencing CA-specific adverse effects (AEs) were switched to lercanidipine for 4 weeks and then rechallenged with their initial treatment for 4 weeks. Results showed that at comparable levels of BP, lercanidipine was associated with a significantly lower incidence of ankle edema, flushing, rash, headache and dizziness compared with other CAs (p < 0.001). After 4 weeks of lercanidipine, mean systolic blood pressure (SBP)/diastolic blood pressure (DBP) was 142.1/86.7 mmHg. After rechallenge with other CAs for 4 weeks, mean SBP/DBP was 141.1/86.7 mmHg. In this open-label study, lercanidipine compared with other CA seems to provide a significant improvement in tolerability with comparable antihypertensive effect. Topics: Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Edema; Endpoint Determination; Female; Flushing; Headache; Heart Rate; Humans; Hypertension; Male; Middle Aged; Patient Dropouts	2003

Article

Year

Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial.

Blood pressure. Supplement, 2003, Volume: 1

The objective of this 8-week open-label study was to compare the tolerability of lercanidipine, a dihydropyridine calcium-channel antagonist (CA), with that of other CAs in the treatment of hypertension. Subjects already taking amlodipine, felodipine, nifedipine gastrointestinal therapeutic system (GITS), or nitrendipine and experiencing CA-specific adverse effects (AEs) were switched to lercanidipine for 4 weeks and then rechallenged with their initial treatment for 4 weeks. Results showed that at comparable levels of BP, lercanidipine was associated with a significantly lower incidence of ankle edema, flushing, rash, headache and dizziness compared with other CAs (p < 0.001). After 4 weeks of lercanidipine, mean systolic blood pressure (SBP)/diastolic blood pressure (DBP) was 142.1/86.7 mmHg. After rechallenge with other CAs for 4 weeks, mean SBP/DBP was 141.1/86.7 mmHg. In this open-label study, lercanidipine compared with other CA seems to provide a significant improvement in tolerability with comparable antihypertensive effect.

Topics: Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Edema; Endpoint Determination; Female; Flushing; Headache; Heart Rate; Humans; Hypertension; Male; Middle Aged; Patient Dropouts

2003

Other Studies

1 other study(ies) available for dihydropyridines and Flushing

Article	Year
Cyclosporin enhances the tendency towards oedema and flushing noted on dihydropyridine calcium channel blockers. British journal of clinical pharmacology, 2002, Volume: 54, Issue:3 Topics: Adolescent; Adult; Amlodipine; Calcium Channel Blockers; Child; Child, Preschool; Cyclosporine; Dihydropyridines; Edema; Female; Flushing; Humans; Hypertension; Infant; Male	2002